Overhauling the US Food and Drug Administration's OTC drug monograph program depends on Congress passing legislation, something agency officials and industry stakeholders are confident will come but aren't predicting when.
The FDA and the Consumer Healthcare Products Association are preparing for changes to monograph procedures that the agency and industry stakeholders negotiated, including a user fee program, and that are included in legislation passed by the House and introduced in the Senate
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?